RxDoctor Payments Data

George Nikias, MD

Gastroenterology · River Edge, NJNPI 1679585236

Payments from drug & device makers

$6,005in general payments, 2019–2025

Across 416 payments — averaging $14.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$740
  • Johnson & Johnson$615
  • Bristol Myers Squibb$607
  • Pfizer$585
  • Takeda Pharmaceuticals U.S.A., Inc.$438
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$6,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,005 in reported general payments places this provider in the 70th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$186,103
Medicare patients
483
Services billed
1,616

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cimzia (2 Pack)Certolizumab Pegol12$65,611
XifaxanRifaximin22$60,655
LinzessLinaclotide22$21,605
Mesalamine27$7,591
MotegrityPrucalopride Succinate13$7,403
Mesalamine ErMesalamine24$6,658
Dexlansoprazole DrDexlansoprazole18$5,356
Ursodiol41$5,228
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates37$2,379
Colestipol Hcl28$2,187
Budesonide DrBudesonide22$1,835
Pantoprazole Sodium121$1,406
Omeprazole78$1,152
Mycophenolate Mofetil15$1,006
Nortriptyline Hcl52$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Cimzia (2 Pack)$57$65,61112 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$740$60,65522 claims
AbbVieLinzess$1,064$21,60522 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$438$7,40313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in River Edge

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →